Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity

American Journal of Clinical Nutrition

Volumn 77, Issue 2, 2003, Pages 300-307

  Chan, Dick C ^a   Watts, Gerald F ^a   Mori, Trevor A ^a   Barrett, P Hugh R ^a   Redgrave, Trevor G ^b   Beilin, Lawrence J ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b NONE

Author keywords

Apolipoprotein B; Chylomicron remnants; Fish oils; Men; Visceral obesity

Indexed keywords

APOLIPOPROTEIN B100; CARBON DIOXIDE; CHOLESTEROL OLEATE; CHYLOMICRON; CORN OIL; DEUTERIUM; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; INTERMEDIATE DENSITY LIPOPROTEIN; ISOTOPE; LEUCINE; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PLACEBO; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; EMULSION; GAS CHROMATOGRAPHY; HUMAN; LIPID METABOLISM; LIPOLYSIS; MALE; MASS SPECTROMETRY; OBESITY; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ZEA MAYS;

EID: 0037307248     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/77.2.300     Document Type: Article

References (37)

1. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Atherosclerosis 1990;10:497-511.
2. Reaven GM. 1988 Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
3. Riches FM, Watts GF, Naoumova RP, et al. Hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 studied with a stable isotope technique in men with visceral obesity. Int J Obes Relat Metab Disord 1998;22:414-23.
4. Riches FM, Watts GF, Hua J, Stewart GR, Naoumova RP, Barrett PH. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999;84:2854-61.
5. Mamo JC, Watts GF, Barrett PH, Smith D, James AP, Pal S. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol 2001:281:E626-32.
6. Chan DC, Watts GF, Barrett PH, Mamo CL, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002 48:278-83.
7. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
8. Pearson TA, McBride PE, Miller NH, Smith SC. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. J Am Coll Cardiol 1996;27:1039-47.
9. Harris WS. n-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65:1645S-54S.
10. Nestel PJ, Connor WE, Reardon MF, Connor S, Wong S, Boston R. Suppression by diets rich in fish oil of very low density lipoprotein production in man. J Clin Invest 1984;74:82-9.
11. Bordin P, Bodamer OA, Venkatesan S, Gray RM, Bannister PA, Halliday D. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Eur J Clin Nutr 1998;52:104-9.
12. Huff MW, Telford DE. Dietary fish oil increases conversion of very low density lipoprotein apoprotein B to low density lipoprotein. Arteriosclerosis 1989;9:58-66.
13. Fisher WR, Zech LA, Stacpoole PW. Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched diet. J Lipid Res 1998;39:388-401.
14. Westphal S, Orth M, Ambrosch A, Osmundsen K, Luley C. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids. Am J Clin Nutr 2000;71:914-20.
15. Redgrave TG, Watts GF, Martins IJ, et al. Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test. J Lipid Res 2001;42:710-5.
16. Martins IJ, Hone E, Chi C, Seydel U, Martins RN, Redgrave TG. Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. J Lipid Res 2000;41:205-13.
17. Gregersen MI, Rawson RA. Blood volume. Physiol Rev 1959;39:307-42.
18. Egusa G, Brady DW, Grundy SM, Howard BV. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J Lipid Res 1983;24:1261-7.
19. Cummings MH, Watts GF, Lumb PJ, Slavin BM. Comparison of immunoturbidimetric and Lowry methods for measuring concentration of very low density lipoprotein apolipoprotein B-100 in plasma. J Clin Pathol 1994;47:176-8.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
21. Mori TA, Croft KD, Puddey IB, Beilin LJ. Analysis of native and oxidized low-density lipoprotein oxysterols using gas chromatography-mass spectrometry with selective ion monitoring. Redox Rep 1996;2:25-31.
22. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.
23. Phair RD, Hammond MG, Bowden JA, Fried M, Fisher WR, Berman M. Preliminary model for human lipoprotein metabolism in hyperlipoproteinemia. Fed Proc 1975;34:2263-70.
24. Illingworth DR, Harris WS, Connor WE. Inhibition of low density lipoprotein synthesis by dietary omega-3 fatty acids in humans. Arteriosclerosis 1984;4:270-5.
25. Watts GF, Cummings MH, Keel JM, et al. Acute hyperinsulinemia decreases hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in normolipidaemic, non-diabetic subjects. Endocrinol Metab Clin North Am 1996;3:253-63.
26. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulin-resistant state. Diabetes Care 1996;19:390-3.
27. Taskinen MR. Lipoprotein lipase in diabetes. Diabetes Metab Rev 1987;3:551-70.
28. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes 1984;33:333-8.
29. Price PT, Nelson CM, Clarke SD. Omega-3 polyunsaturated fatty acid regulation of gene expression. Curr Opin Lipidol 2000;11:3-7.
30. Lu G, Windsor SL, Harris WS. Omega-3 fatty acids alter lipoprotein subfraction distributions and the in vitro conversion of very low density lipoproteins to low density lipoproteins. J Nutr Biochem 1999;10:151-8.
31. Sigurdsson G, Nicoll A, Lewis B. Metabolism of very low density lipoproteins in hyperlipidaemia: studies of apolipoprotein B kinetics in man. Eur J Clin Invest 1976;6:167-77.
32. Benoist F, Grand-Perret T. Apo B-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Arterioscler Thromb Vasc Biol 1996;16:1229-35.
33. Harris WS, Windsor SL. n-3 Fatty acid supplements reduce chylomicron levels in healthy volunteers. J Appl Nutr 1991;43:5-15.
34. Zampelas A, Murphy M, Morgan LM, Williams CM. Postprandial lipoprotein lipase, insulin and gastric inhibitory polypeptide responses to test meals of different fatty acid composition: comparison of saturated, n-6 and n-3 polyunsaturated fatty acids. Eur J Clin Nutr 1994;48:849-58.
35. Willumsen N, Vaagenes H, Lie O, Rustan AC, Berge RK. Eicosapentaenoic acid, but not docosahexaenoic acid, increases mitochondrial fatty acid oxidation and upregulates 2,4-dienoyl-CoA reductase gene expression in rats. Lipids 1996;31:579-92.
36. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000;71:1085-94.
37. Watts GF, Riches FM, Humphries SE, Talmud PJ, van Bockxmeer FM. Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity. J Lipid Res 2000;41:481-8.